Jupiter Endovascular Exits Stealth with $21 Million Funding
Menlo Park, Calif., Medtech Ready for Pivotal Trial
August 15, 2024
Jupiter Endovascular, a subsidiary of Neptune Medical, has exited stealth mode with $21 million in new financing. The funding will support a pivotal trial for the company's pulmonary embolism treatment.
Jupiter Endovascular is developing a new class of endovascular procedures. Endovascular procedures are minimally invasive procedures that use catheters and other instruments to treat conditions inside the body. Jupiter Endovascular's technology is designed to treat pulmonary embolism, a life-threatening condition that occurs when a blood clot blocks an artery in the lungs.
The $21 million in new funding will allow Jupiter Endovascular to complete its pivotal trial and submit its device for regulatory approval. The company plans to begin enrolling patients in the trial later this year.
Key Points
- Jupiter Endovascular has exited stealth mode with $21 million in new financing.
- The funding will support a pivotal trial for the company's pulmonary embolism treatment.
- Jupiter Endovascular is developing a new class of endovascular procedures.
- The company's technology is designed to treat pulmonary embolism, a life-threatening condition that occurs when a blood clot blocks an artery in the lungs.
- Jupiter Endovascular plans to begin enrolling patients in the trial later this year.
About Jupiter Endovascular
Jupiter Endovascular is a medical technology startup based in Menlo Park, California. The company is developing a new class of endovascular procedures to treat pulmonary embolism.
About Neptune Medical
Neptune Medical is a medical technology company based in Menlo Park, California. The company develops and manufactures minimally invasive devices for the treatment of cardiovascular and pulmonary diseases.
Sources
- Neptune Medical sprouts Jupiter Endovascular to tackle pulmonary embolism
- Neptune Medical launches Jupiter Endovascular with $21M to develop PE embolization device
- Neptune Medical spins out Jupiter Endovascular with $21M to tackle pulmonary embolism
Comments